Does UnitedHealthcare Cover Zepbound, Wegovy and Other GLP-1s for Weight Loss in 2026?

Start with the kind of UHC coverage you have. It decides almost everything below.

• Your employer plan covers weight-loss drugs: get the plan's advance approval, called prior authorization or PA, then add the maker's savings card.
• Your employer plan excludes them: a sleep apnea, heart or liver diagnosis can still open a separate door. Ask HR, too, whether the coverage can be added.
• You have a UHC Individual & Family marketplace plan: look up each drug by name in your plan's drug list before you count on coverage.
• You have a UHC or AARP Medicare plan: Medicare's GLP-1 Bridge is the main door, at $50 a month if you meet its rules.
• The answer is still no: the makers sell Zepbound and Wegovy directly, at the same price whether you have insurance or not.

The short version, by situation:

• Covered at work: the maker's savings card, for about $25 a month.
• On Medicare: the GLP-1 Bridge, at $50 a month.
• Not covered, lowest FDA-approved price: the Wegovy pill from NovoCare, about $150 at the first dose and about $300 at the usual doses.
• Not covered, and you want Zepbound: Lilly's KwikPen or vials, about $300 to $450 a month by dose.
• You want someone else to handle the paperwork: Ro or Mochi Health help with the prior authorization.

Every way to pay for a GLP-1 with a UnitedHealthcare plan, option by option

UHC covers Zepbound, plus Lilly's savings card: Zepbound with coverage

This is Lilly's copay coupon for commercial plans, meaning coverage through work or the marketplace. Your UHC plan must already cover Zepbound.

You can pay as little as $25 for a one-month fill of the single-dose pen. The card pays up to $100 a month and up to $1,300 a year, for up to 13 fills.

The pen type matters on UHC. Optum Rx's standard drug list covers the single-dose pen and excludes the KwikPen, a multi-dose pen, and the vials. The current card runs through December 31, 2026.

UHC covers Wegovy, plus Novo's savings card: Wegovy with coverage

Novo Nordisk's card works the same way. You pay as little as $25, and the card pays up to $100 for each one-month fill of the pen or the pill.

There is a UHC wrinkle. Its weight-loss policy says Wegovy tablets are typically excluded from coverage, so check that your plan lists the pill before you count on it.

Novo's terms shut the card off on plans with copay accumulator or maximizer programs. Both are plan rules that change how coupon money counts toward your deductible.

The card still helps when UHC says no. The pharmacist runs it as a second payer, and you pay Novo's self-pay price at a regular pharmacy.

UHC or AARP Medicare plan plus the GLP-1 Bridge: best on Medicare

Since July 1, 2026, eligible members of Medicare drug plans, UHC and AARP plans included, can get Wegovy, Foundayo or the Zepbound KwikPen for $50 a month. Who qualifies is explained in the Medicare section below.

Lilly self-pay KwikPen or vial: Zepbound if your plan says no

Lilly sells the KwikPen and vials at the same self-pay prices to everyone, insured or not. Since March 16, 2026, the KwikPen has sold at that price in major pharmacies too, not only through LillyDirect, Lilly's online pharmacy.

• 2.5 mg: about $300 for four weeks.
• 5 mg: about $400.
• 7.5 mg to 15 mg: about $450, if you refill within 45 days of your last delivery.
• Late refill: about $500 at 7.5 mg and about $700 from 10 mg up.

Self-pay money does not count toward your UHC deductible. Lilly's card terms say so plainly.

NovoCare self-pay Wegovy: Wegovy if your plan says no

NovoCare is Novo Nordisk's direct program. Its prices are the same for insured and uninsured women, and the pill is the cheaper format.

• Pill: about $150 at the first dose, about $200 at the second, then about $300 a month.
• Pen, first two fills: about $200 each at the two starting doses, for new patients through December 31, 2026.
• Pen after that: about $350 a month, or about $400 for the highest dose, Wegovy HD.

You can fill through NovoCare Pharmacy or use the savings offer at a regular pharmacy.

Ro: best for full-service insurance help

Ro's team checks whether your plan covers Ozempic, Wegovy or the single-dose Zepbound pen, then helps with the prior authorization. Once approved, you pay your UHC copay for the drug.

The Ro Body membership is about $150 a month after a first month of about $40. Prepaying a year brings it to about $75 a month, and the medicine is billed on top.

Ro's weight program is not offered in Hawaii, Louisiana, Mississippi or Virginia. Ro holds 3.9 stars on Trustpilot from about 6,800 reviews, and our Ro insurance review has the details.

Mochi Health: lowest membership with PA help

Mochi's team helps with insurance questions, prior authorizations and letters of medical necessity. That letter is your prescriber's written case for why you need the drug.

The membership is about $80 a month, with the first month free on the one-month plan, though not in every state. A prepaid year brings it to about $50 a month, and HSA or FSA money is accepted.

With private insurance, Mochi also sells a Covered With Mochi plan, at about $120 for six months or about $200 for a year. Visits are billed to your plan, and the medicine is billed separately.

Mochi holds 4.5 stars on Trustpilot from about 19,500 reviews. Our Mochi Health insurance review has the rest.

JoinSkinny compounded semaglutide: a cash option outside your plan

JoinSkinny charges about $150 every 28 days for compounded semaglutide, and the price stays the same as the dose rises. It is not Wegovy, it is not FDA-approved, and you pay cash, never through UHC. Our compounded GLP-1 guide explains where it stands.

Does UnitedHealthcare cover GLP-1s for weight loss in 2026?

On work plans, only if your employer chose to. UHC's own policy calls its weight-loss drug program optional, for clients that elected to cover these drugs.

UHC's standard commercial drug list, effective September 1, 2026, does not list Wegovy, Zepbound, Foundayo or Saxenda. They come in through that optional program instead.

Where the program is switched on, here is where each drug stands.

• Wegovy pen and Wegovy HD: covered with a prior authorization.
• Wegovy pill: named in the policy, but UHC notes the tablets are typically excluded.
• Zepbound: covered with a prior authorization. On Optum Rx's standard list, that means the single-dose pen, not the KwikPen or vials.
• Foundayo: Lilly's daily GLP-1 pill joined UHC's weight-loss policy in May 2026.
• Saxenda: an older daily shot that its maker is discontinuing. The FDA lists supply until January 2027, and Optum Rx's 2027 standard list excludes it.

Diabetes drugs are a separate lane. UHC's commercial list puts Ozempic and Mounjaro on tier 2 of its diabetes section, with a prior authorization. A tier is the price level a drug sits on, and lower tiers cost you less.

Don't count on Ozempic or Mounjaro as a way around a weight-loss exclusion. Our Ozempic insurance guide explains why.

Does UnitedHealthcare cover Zepbound?

It can, and the reason on your prescription decides which door you use. The FDA has approved Zepbound for two uses.

• Weight: for adults with a BMI of 30 or more, or 27 or more with a weight-related condition, alongside diet and activity.
• Sleep apnea: for moderate to severe obstructive sleep apnea in adults with obesity. In this condition, the airway keeps closing during sleep.

On a plan with weight-loss coverage, UHC reviews Zepbound under its weight-loss policy. On a plan without it, UHC has a separate sleep apnea policy for Zepbound, in force since September 1, 2026.

That sleep apnea door is narrow. It asks for a sleep study, a BMI of 30 or more and a past diet attempt, among other proof listed in the prior authorization section below.

Format matters too. Optum Rx's standard list covers the single-dose pen and excludes the KwikPen and vials, in 2026 and again for 2027. Our Zepbound insurance guide covers the drug in more depth.

Does UHC cover Wegovy?

The same employer rule applies, with one difference. Wegovy has two approved uses beyond weight, and UHC reviews them even on plans that exclude weight loss.

• Heart risk: since March 2024, Wegovy is approved to lower the risk of heart attack and stroke in adults with heart disease and excess weight.
• Liver disease: since August 2025, it is approved for MASH with moderate to advanced scarring of the liver.

UHC's separate Wegovy policy, in force since May 1, 2026, covers those two uses on plans without weight-loss coverage. The heart route has strict rules, listed in the prior authorization section.

The Wegovy pill, approved in December 2025, sits on drug lists as its own entry. Look up the pill and the pen separately. Our Wegovy insurance guide has the drug-level details.

Foundayo is Lilly's daily GLP-1 pill, approved in April 2026. It sits in UHC's weight-loss policy, and our Foundayo cost page has its prices.

Why the same UHC card can give two different answers: your employer and Optum Rx

UnitedHealthcare sells two kinds of work plans. Your employer's choice sits at the center of both.

• Fully insured plan: your employer buys a ready-made UHC plan. Weight-loss drugs are in it only if the employer bought that option.
• Self-funded plan: your employer pays claims itself and pays UHC to run the plan. Your employer decides on weight-loss drugs.
• Optum Rx: a pharmacy benefit manager, or PBM, runs a plan's drug list and pays pharmacies. Optum Rx is UHC's PBM, and both belong to UnitedHealth Group.
• Carve-outs: some employers keep UHC for medical care but hire another PBM, such as Express Scripts or CVS Caremark. Then that PBM's drug list applies.

On Optum Rx's standard lists, Wegovy and the Zepbound pen carry a ++ code. Optum's legend calls it a benefit design option, meaning your plan decides coverage.

Your card holds the clues. The Rx BIN and PCN lines tell the pharmacy which company processes your drug claims. The pharmacy phone line on the back usually reaches that company.

UHC prior authorization for Zepbound and Wegovy: what the plan asks

Prior authorization is the plan's approval before it pays. UHC publishes its criteria, and the current weight-loss version took effect on October 1, 2026.

• BMI: 30 or more, or 27 or more with a weight-related condition. UHC's examples are high cholesterol, high blood pressure, type 2 diabetes and sleep apnea.
• Lifestyle: the drug must go alongside lifestyle changes, such as a reduced-calorie diet, exercise or a behavior program. The policy sets no minimum length.
• First approval: five months for Wegovy, six months for Zepbound and Foundayo.
• Renewal: proof of at least 5% weight loss from your starting weight, plus continued lifestyle changes. Renewals last 12 months.
• Still stepping up the dose: if you have been on the drug six months or less and have not reached your maintenance dose, UHC grants one extra six-month approval.
• Other limits: the policy does not require step therapy, which means trying another drug first. It does say supply limits may apply.

Plans without weight-loss coverage use UHC's separate policies instead. Their rules are stricter.

• Zepbound for sleep apnea: a BMI of 30 or more and a sleep study showing at least 15 breathing events an hour. You also need one past diet attempt.
• More sleep apnea rules: symptoms despite regular use of a CPAP machine, or a reason you can't use one. You must not have diabetes.
• Who prescribes: a sleep specialist, lung doctor or ear, nose and throat doctor, or a doctor experienced in sleep apnea.
• Sleep apnea renewal: the first approval lasts six months. If you use CPAP, renewal asks for at least 10% weight loss.
• Wegovy for heart risk: age 45 or older, a BMI of 27 or more, and a past heart attack, stroke or leg artery disease with symptoms.
• More heart rules: you take standard heart medicines unless you can't, and you do not have diabetes. Approval lasts 12 months.
• Wegovy for MASH: a liver scan or biopsy showing moderate to advanced scarring, with a liver or digestive specialist involved.

Dose steps, which matter at renewal, are in our Zepbound dosage guide and Wegovy dosage guide.

For women over 40: what counts and what does not

Menopause weight gain on its own does not qualify. Menopause is not an approved use for either drug, and UHC's policy does not list it.

What counts is your BMI and the conditions in your chart. Blood pressure, blood sugar and cholesterol often shift in the 40s and 50s, so make sure each diagnosis is written down before the request goes out.

Sleep apnea deserves a look too. In the Wisconsin Sleep Cohort Study, women after menopause were more likely to have sleep-disordered breathing than women before it, even after accounting for age and body size.

Your 45th birthday matters as well. It is the minimum age for UHC's Wegovy heart route.

Our guide to perimenopause weight-loss medication explains how these drugs fit this stage of life.

How to check your own UHC plan in 5 minutes

You do not need to wait for a denial letter. Have your UHC card and your member login ready.

• Log in to myuhc.com or the UnitedHealthcare app: the drug price tool usually sits under pharmacy or prescriptions.
• Or use the Optum Rx app or website: if your card names Optum Rx, its drug search shows your plan's list.
• Search each drug by name: Zepbound, Wegovy, the Wegovy pill and Foundayo, one by one.
• Read the codes: PA means prior authorization. QL, a quantity limit, caps each fill, and ST, step therapy, means trying another drug first.
• Check the tier and the format: the tier sets your share of the cost. Make sure the Zepbound entry is the single-dose pen, the one the $25 card names.
• Not covered or excluded: this usually means a benefit exclusion. Your employer did not buy weight-loss coverage.

Questions for HR or the pharmacy line on your card

• Is our plan self-funded? If yes, your employer decides on weight-loss drugs.
• Did we elect UHC's weight-loss drug program? Some employers add it as a rider, an extra benefit bought on top of the plan.
• Is our drug benefit run by Optum Rx or carved out to another PBM? The answer tells you whose drug list to search.
• How are coupons counted? Ask whether the plan uses a copay accumulator or maximizer program.
• Does anything change on January 1, 2027? Fall is open enrollment season, and many plans announce next year's changes now.

Read your 2027 plan documents as soon as they arrive. If a spouse has work coverage, check that plan's weight-loss rules too.

What you'll pay when UHC covers it

Covered does not mean one fixed price. Three parts of your plan decide what you pay at the counter.

• Copay: a flat amount for each fill. This is the easiest case for the savings cards.
• Coinsurance: a percentage of the plan's price for the drug. Even a small share adds up fast on a drug that lists above $1,000 a month.
• Deductible: what you pay yourself each year before the plan starts sharing costs. Until you meet it, you may owe the plan's full price.

The list price is the maker's official price before discounts. Coinsurance and deductibles are figured from it, not from the self-pay prices.

Wegovy lists at about $1,350 a month in 2026. Novo Nordisk cuts that to $675 on January 1, 2027, so a coinsurance share of Wegovy should fall with it.

The savings card fine print

• Zepbound card: the single-dose pen only, up to $100 a month and $1,300 a year, for up to 13 fills. The current card expires on December 31, 2026.
• Wegovy card: the pen, or the pill if your plan lists it, up to $100 for a one-month fill. It is off limits on accumulator and maximizer plans.
• Who is left out: anyone enrolled in Medicare, Medicaid or another government drug plan, even with a work plan on top.
• The January trap: a high deductible resets each January, so the first fills of the year can cost far more than $25.

Activation steps are on our Zepbound savings page and our Wegovy savings card page.

UHC denied it or your plan excludes weight-loss drugs: what still works

Read the denial letter first. A denial for missing paperwork can be fixed, but a plan exclusion usually cannot be appealed.

• Sleep apnea route: UHC's separate Zepbound policy reviews moderate to severe sleep apnea on plans without weight-loss coverage.
• Heart or liver route: UHC's separate Wegovy policy reviews heart risk and MASH on those same plans.
• Formulary exception: the formulary is the plan's list of covered drugs. Your prescriber can ask the plan to cover a drug it leaves off, with a clear medical reason.
• Letter of medical necessity: your prescriber's written case, with your BMI, diagnoses and past treatments. It strengthens any request or appeal.
• Employer rider: ask HR whether weight-loss coverage can be added at the next renewal.
• Open enrollment: compare plans on these drugs, not just on premiums, including a spouse's plan.

If the denial was about missing proof, appeal it. You have 180 days to file an internal appeal, and the plan must decide within 30 days for a drug you have not started.

If UHC says no again, you can ask for an independent external review. The full appeal steps are in our Zepbound insurance guide.

Not covered by UHC: the cheapest ways to get a GLP-1

A no from UHC does not send you to the list price. The makers sell directly, at the same price for everyone.

• Wegovy pill from NovoCare: about $150 a month at the first dose, then about $300 at the usual doses.
• Zepbound KwikPen or vials from Lilly: about $300 to $450 a month by dose, at LillyDirect or major pharmacies.
• Wegovy pen from NovoCare: about $350 a month after two starter fills at about $200, for new patients through December 31, 2026.
• Wegovy card at your usual pharmacy: when UHC rejects the claim, the card brings the price down to Novo's self-pay price.
• Zepbound card for plans that skip the single-dose pen: from about $500 a month. That costs more than the on-time self-pay KwikPen at every dose.
• TrumpRx.gov: a government site that lists the makers' self-pay prices. It never uses your insurance.

Compounded semaglutide and tirzepatide cost less, but they are not FDA-approved and UHC does not pay for them. Our compounded GLP-1 guide explains the trade-offs.

Our GLP-1 without insurance page ranks every cash route. For Zepbound alone, see the cheapest ways to get Zepbound.

UnitedHealthcare Medicare Advantage: the $50 GLP-1 Bridge

Medicare's drug coverage, called Part D, still cannot pay for drugs used only for weight loss. The GLP-1 Bridge is a separate federal program that runs alongside your UHC Medicare plan.

• What it covers: Wegovy pen or pill, Foundayo and the Zepbound KwikPen. Single-dose Zepbound pens and vials are left out.
• Price: $50 for a one-month supply. It does not count toward your Part D deductible or yearly limit, and Extra Help does not lower it.
• BMI of 35 or more: you qualify with no other condition.
• BMI of 30 or more: you also need heart failure with preserved ejection fraction, uncontrolled high blood pressure, or kidney disease at stage 3a or worse.
• BMI of 27 or more: you also need prediabetes, a past heart attack or stroke, or blocked leg or arm arteries with symptoms.
• Who is left out: people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease. So is anyone whose Part D plan already pays for a GLP-1.
• Plans that qualify: UHC and AARP-branded Medicare Advantage plans with drug coverage, stand-alone Part D plans, Special Needs Plans and employer retiree plans.
• How it starts: your prescriber sends the prescription and confirms you follow a diet and exercise program. Approval lasts through December 31, 2027.

Part D can still cover Zepbound for sleep apnea or Wegovy for heart risk. In 2026, your out-of-pocket costs for covered drugs stop at $2,100 for the year.

Turning 65 on a UHC work plan

Once you enroll in Medicare, the savings cards stop, even if you keep a work plan. Plan the switch a few months ahead.

If you qualify for the Bridge on Zepbound, ask for a KwikPen prescription timed with your Medicare start. If you have sleep apnea, compare Part D plans on their Zepbound coverage, not just their premium.

UHC Community Plan, the Medicaid side

UHC Community Plan follows your state's Medicaid rules. KFF counted 13 state Medicaid programs covering GLP-1s for obesity in January 2026.

States can also pull back. UHC Community Plan of Massachusetts stopped covering weight-loss drugs on July 3, 2026, following MassHealth.

Medicaid must still cover uses such as diabetes, heart disease and sleep apnea, usually after a prior authorization. The savings cards do not apply.

What a year costs on a UHC plan, covered vs not

Pen boxes and Lilly's self-pay fills last four weeks, so a year holds 13 fills. Wegovy pill bottles last 30 days, so a year holds about 12.

• Covered, copay plan, savings card: about $25 a fill, so about $300 to $325 a year.
• UHC Medicare plan with the Bridge: $50 a fill, so about $600 to $650 a year.
• Covered, with Mochi's prepaid membership: about $590 for the year plus about $325 in card copays, so about $910.
• Covered, with Ro's prepaid membership: about $890 for the year plus about $325 in copays, so about $1,210.
• Not covered, JoinSkinny compounded semaglutide: 13 cycles at about $150, so about $1,940. It is not FDA-approved.
• Not covered, NovoCare pill: one bottle each at about $150 and $200, then about $300, so about $3,340.
• Not covered, NovoCare pen, starting before 2027: two starter fills at about $200, then about $350, so about $4,240.
• Not covered, NovoCare pen, starting in 2027: about $350 a fill if the starter offer is not renewed, so about $4,540.
• Not covered, Lilly self-pay, staying at 5 mg: one fill at about $300, then about $400, so about $5,090.
• Not covered, Lilly self-pay, moving to 7.5 mg or more: about $300, then $400, then about $450 with on-time refills, so about $5,640.
• No program at all: about $17,500 a year for Wegovy at its 2026 list price, and more than $13,000 for Zepbound.

A high-deductible plan lands in between. The gap between the first line and the last is why an afternoon with your plan documents pays off.